Revolutionising Diabetes Detection with Home Testing

Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.

Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.

By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.

Revolutionising Diabetes Detection with Home Testing

Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.

Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.

By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.

GTT@home Logo - Digostics Orange (1)

The Future of Diabetes Testing, Today

Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.

We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.

GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.

Medway NHS Foundation Trust latest maternity service to implement GTT@home

Digostics and Medway NHS Foundation Trust have announced a partnership to offer remote oral glucose tolerance testing to expectant mothers at risk of gestational diabetes mellitus (GDM).  This collaboration makes Medway the latest trust to adopt GTT@home.

“Our aim is to embrace digital technology so we can provide high quality care. The introduction of GTT@home is helping us to achieve this as our community midwives, who would have managed the workload associated with the traditional clinic-based test, can now focus more of their time and expertise on other critical areas of antenatal and postnatal care.”

Associate Director of Midwifery and Ambulatory Gynaecology at Medway NHS Foundation Trust

 

 

Medway NHS Foundation Trust latest maternity service to implement GTT@home

“Our aim is to embrace digital technology so we can provide high quality care. The introduction of GTT@home is helping us to achieve this as our community midwives, who would have managed the workload associated with the traditional clinic-based test, can now focus more of their time and expertise on other critical areas of antenatal and postnatal care.”

Associate Director of Midwifery and Ambulatory Gynaecology at Medway NHS Foundation Trust

 

GTT@home Logo - Digostics Orange (1)

The Future of Diabetes Testing, Today

Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.

We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.

GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.

A Real-World Assessment of GDM Home Testing at University Hospital Southampton

Download a case study showcasing the results from University Hospital Southampton NHS Foundation Trust's implementation of GTT@home for gestational diabetes.

New Project - 2024-01-31T155702-975-1

100% of surveyed expectant mothers using GTT@home recommended it over in-clinic testing.

100% of surveyed maternity staff using GTT@home recommend the solution over in-clinic testing.

Accurate OGTT Results from the Comfort of Home

Discover how GTT@home provides reliable results that match those obtained in a clinical setting by downloading the associated study.

"GTT@home has an excellent correlation and low bias compared to a reference glucose analyser, with an excellent agreement in categorisation of glucose tolerance."

Professor Steve Luzio, Swansea University

Datasheet Thumbnail for Poster

Book a Meeting at MedTech Forum 2024

To learn more about Digostics and GTT@home while at MedTech, book a consultation with our  Singapore representative, Lewis Owens.

Could GTT@home be of assistance to your patients?

Please request contact by completing the form below.